December 12, 2001
Apotex Inc. Expands GTA Operations, Creates 300 Jobs
TORONTO, ONTARIO, CANADA – Today, Apotex Inc. is holding a job fair for over 300 available positions in the Greater Toronto Area. The job fair, at the Westin Prince Hotel in Toronto, is for full and part-time employment in multiple departments within the
organization...
November 19, 2001
New Generic Pharmaceutical Approvals
To Impact Negatively on Sales of Paladin Labs
TORONTO, ONTARIO, CANADA – Apotex Inc. announced today that it has received its Notice of Compliance from the Federal Government to sell Apo-Flavoxate tablets 200 mg, a generic version of the brand Urispas™, sold by Paladin Labs
(PLB)...
October 25, 2001
Deferiprone
Safety and Efficacy Confirmed at International Thalassemia Conference
TORONTO, ONTARIO, CANADA –
Apotex Research Inc. reports today that the 8th
International Conference on Thalassemia and Hemoglobinopathies, held
October 18-21 in Athens, Greece, provided a strong endorsement for the use
of Deferiprone (Ferriprox™) in the treatment of iron overload in
thalassemia patients...
October 15, 2001
$5-Million Donation Gives U Of T Pharmacy Students
Latest Tools For Learning
TORONTO, ONTARIO, CANADA – A $5-million gift from Canadian pharmaceutical company Apotex Inc. will allow the University of Toronto’s Faculty of Pharmacy to establish two new educational facilities designed to produce Canada’s next leaders in pharmacy research and professional practice...
September 13, 2001
UBC Receives Key Donation from Major
Canadian-owned Pharmaceutical Company for New Pharmacy Practice Centre
TORONTO, ONTARIO, CANADA – The Apotex Group of Companies announced
today a donation of $150,000 over 5 years for the UBC Pharmacy Practice Centre...
June 29, 2001
Apotex: Number 1 in R&D in the Pharmaceutical
Industry
TORONTO, ONTARIO, CANADA – The annual ranking of
Canada’s top 100 Corporate R&D spenders has placed Apotex number one in the
pharmaceutical sector – the first time that a Canadian-owned company has led spending
in the industry. Apotex
spent more money on R&D in 2000 than any other firm from the pharmaceutical sector
that was listed in this year’s top 100...
